Medical Device Certifications
European Union
Canfield’s AI decision support solutions DEXI®* and Lesion Visualizer* have been CE marked under the EU Medical Device Regulation (MDR) for lesion assessment in Europe.
- CE marking under Regulation (EU) 2017/745 on medical devices (EU MDR).
United Kingdom
Canfield’s AI decision support solutions DEXI®* and Lesion Visualizer* have been CE marked under EU MDR (Class IIb and IIa) and are accepted and registered with the UK Medicines & Healthcare products Regulatory Agency (MHRA) for the Great Britain market.
- Accepted CE marking under Regulation (EU) 2017/745 on medical devices (EU MDR).
Intended for trained clinicians and healthcare professionals experienced in skin cancer diagnosis, the AI tools support the standardized and objective assessment of suspicious cutaneous lesions. DEXI* is classified as a Class IIb medical device and supports clinical decision-making for skin cancer assessment. Lesion Visualizer* is classified as a Class IIa medical device and supports lesion change detection.
Lesion Visualizer
MDR approved clinical decision support for smarter lesion assessment.
CE Marked | EU MDR Class IIaDEXI®
The leading dermoscopy-based medical device where AI supports your skin cancer assessment.
CE Marked | EU MDR Class IIb*Available in the European Union and United Kingdom. In all other countries, DEXI and Lesion Visualizer are for research use only.
*DEXI & Lesion Visualizer are available within the DermaGraphix® platform.